Similar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn's Disease After Switching From CT-P13 to SB2 Infliximab Biosimilar

被引：3
|
作者：
Pagnini, Cristiano [1 ]
Di Paolo, Maria Carla [1 ]
De Angelis, Giulia [1 ]
Torcolacci, Federica [1 ]
Milano, Michele [1 ]
Trinca, Daniela [1 ]
Porciello, Roberto [2 ]
Graziani, Maria Giovanna [1 ]
机构：
[1] S Giovanni Addolorata Hosp, Dept Gastroenterol & Digest Endoscopy, Rome, Italy
[2] S Giovanni Addolorata Hosp, Dept Dermatol, Rome, Italy
来源：
INFLAMMATORY BOWEL DISEASES | 2020年 / 26卷 / 08期
关键词：
infliximab biosimilar; CT-P13; BS2; Crohn's disease; psoriasis; IMMUNOGENICITY;
D O I：
10.1093/ibd/izaa128
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：E83 / E84
页数：2
相关论文
共 50 条
  • [31] Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease
    Katsanos, Konstantinos H.
    Papamichael, Konstantinos
    Cheifetz, Adam S.
    Christodoulou, Dimitrios K.
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (03) : 465 - 466
  • [32] ECCO 2018: British Observational Study shows Comparability of Iinfliximab Biosimilar CT-P13 with Reference Infliximab and Adalimumab in Patient with Crohn's Disease (CD)
    不详
    VISCERAL MEDICINE, 2018, 34 (02) : 158 - 158
  • [33] Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis
    Hanzel, Jurij
    Bukkems, Laura H.
    Gecse, Krisztina B.
    D'Haens, Geert R.
    Mathot, Ron A. A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (10) : 1309 - 1319
  • [34] Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease
    Martin-Gutierrez, Nerea
    German Sanchez-Hernandez, Jose
    Rebollo, Noemi
    Pordomingo, Alejandra F.
    Munoz, Fernando
    Jose Otero, Maria
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2022, 29 (04) : 222 - 227
  • [35] PHASE III RANDOMIZED CONTROLLED TRIAL TO COMPARE BIOSIMILAR INFLIXIMAB (CT-P13) WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH ACTIVE CROHN'S DISEASE: 1-YEAR MAINTENANCE AND SWITCHING RESULTS
    Ye, Byong Duk
    Kim, Young Ho
    Pesegova, Marina
    Alexeeva, Olga
    Osipenko, Marina
    Lahat, Adi
    Dorofeyev, Andriy
    Salamon, Agnes
    Fishman, Sigal
    Levchenko, Olena
    Cheon, Jae Hee
    Scribano, Maria Lia
    Mateescu, Radu-Bogdan
    Lee, Kang-Moon
    Eun, Chang Soo
    Lee, Sang Joon
    Lee, Sung Young
    Schreiber, Stefan
    GASTROENTEROLOGY, 2018, 154 (06) : S167 - S168
  • [36] Immunogenicity after switching from reference infliximab to biosimilar in children with Crohn's disease
    Sieczkowska, J.
    Jarzebicka, D.
    Oracz, G.
    Meglicka, M.
    Dadalski, M.
    Kierkus, J.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S413 - S414
  • [37] SWITCHING FROM INFLIXIMAB ORIGINATOR TO THE BIOSIMILAR (CT-P13) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE STUDY ABOUT EFFECTIVENESS AND SAFETY
    Annulli, G.
    Quatraccioni, C.
    Daretti, L. M.
    Antuono, S.
    Guardati, P.
    Calzolari, M.
    Benedetti, A.
    Di Sario, A.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 : S134 - S135
  • [38] Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients
    Pierik, Marieke J.
    van der Meulen, Andrea E.
    van der Linde, Klaas
    Lutgens, Maurice
    Kuijvenhoven, Johan P.
    Akol, Halil
    Klompmaker, Ids J.
    Sikkens, Michelle S. G.
    van Megen, Yvonne J. B.
    Stoop, Corinne M.
    Bloemsaat-Minekus, Joanne P. J.
    Dijkstra, Gerard
    CROHNS & COLITIS 360, 2022, 4 (03)
  • [39] Unchanged infliximab serum concentrations after switching from the originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease: Results from a prospective study (SECURE)
    Strik, A.
    van de Vrie, W.
    Bloemsaat-Minekus, J.
    Nurmohamed, M.
    Bossuyt, P.
    Bodelier, A.
    Rispens, T.
    van Megen, Y.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S477 - S478
  • [40] Letter: treatment with subcutaneous CT-P13 in Crohn's disease patients with intravenous infliximab failure
    Caron, Benedicte
    Fumery, Mathurin
    Netter, Patrick
    Peyrin-Biroulet, Laurent
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (04) : 508 - 509
12345